Drug Trial Radar · NCT06195306
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Jan 1, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 74 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3 fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.
Conditions
- Breast Atypical Hyperplasia
- Breast Carcinoma
- Breast Ductal Carcinoma In Situ
- Breast Lobular Carcinoma In Situ
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood samples
MammographyProcedure
Undergo mammography
Omega-3-Acid Ethyl EstersDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
Random Periareolar Fine-Needle AspirationProcedure
Undergo RPFNA
TamoxifenDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in serum adiponectinTime frame: From baseline up to end of treatment (6 months)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.